


Please type a plus sign (+) in this box

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~



Substitute for form 1449A/PTO

(modified)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 5

<p>6 (2001) 3 TRADEMARK OFFICE Substitute for form 1449A/PTO</p> <p>(modified)</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<p><i>Complete if known</i></p>	
				Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	03764.P142
Sheet	1	of	5		

## U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
<i>SD</i>		4,708,718		Daniels	11/24/1987	
		5,151,100		Abele et al.	9/29/1992	
		5,180,366		Woods	1/19/1993	
		5,356,388		Sepetka et al.	10/18/1994	
		5,380,307		Chee et al.	1/10/1995	
		5,380,747		Medford et al.	1/10/1995	
		5,462,523		Samson et al.	10/31/1995	
		5,496,311		Abele et al.	3/5/1996	
		5,538,504		Linden et al.	7/23/1996	
		5,569,197		Helmus et al.	10/29/1996	
		5,588,962		Nicholas et al.	12/31/1996	
		5,652,059		Margel	7/29/1997	
		5,770,222		Unger et al.	6/23/1998	

RECEIVED

AUG - 7  
2000

FC 3700 MAIL ROOM

## FOREIGN PATENT DOCUMENTS

**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.




Exhibit Disclosure Number: 1800, 2

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) in this box

Under the Paperwork Reduction Act of 2005, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A (07-01)</p> <p>(modified)</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<p><i>Complete if known</i></p>	
				Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	03764.P142
Sheet	2	of	5		

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) in this box



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/RPT (modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if known</b>	
Sheet	3	of	5	Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Assigned
				Attorney Docket Number	03764.P142

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>S</i>		RAHIMTOOLA S. "The Hibernating Myocardium", Am. Heart Journal, 1989, pgs 211-221, Vol. 117, No. 1.	
		CHILIAN W. et al., "Microvascular Occlusions Promote Coronary Collateral Growth", Am. J Physiol, 1990, pgs H1103-11.	
		SCHAPER W., "Angiogenesis In The Adult Heart" Basic Res Cardiol, 1991, pgs 51-56, Vol 86 Suppl.	
		RJESSEN R. et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies" JACC, April 1994, pgs 1234-44, Vol. 23, No. 5.	
		KERSTEN J. et al., "Modulation of Coronary Collateral Angiogenesis: A Canine Model of Neovascularization Induced by Chronic Ischemia", J Card Surg, 1995, pgs 354-7, Vol. 10.	TC 3700
		SCHAPER W. et al., "Molecular Mechanisms of Coronary Collateral Vessel Growth", Circulation Research, November 1996, pgs 911-919, Vol. 79, No. 5.	AUG 7 2001
		BRIEGER D. et al., "Local Drug Delivery Systems And Prevention Of Restenosis", Cardiovascular Research, 1997, pgs 405-413, Vol. 35.	MAIL ROOM
		ITO W. et al., "Angiogenesis But Not Collateral Growth is Associated With Ischemia After Femoral Artery Occlusion", Am. J. Physiol., 1997, pgs. H1255-1265, Vol. 273.	RECEIVED
		TYAGI S., "Vasculogenesis and Angiogenesis: Extracellular Matrix Remodeling in Coronary Collateral Arteries of the Ischemic Heart", Journal of Cellular Biochemistry, 1997, pgs 388-394, Vol. 65.	RECD
		SAUNDERS M. et al., "Release of Granulocyte-Macrophage Colony Stimulating Factor by Human Cultured Airway Smooth Muscle Cells: Suppression by Dexamethasone", Br J Pharmacol, Feb 1997, pgs 545-546, Vol. 120, No. 4.	
		ITO W. et al., "Monocyte Chemoattractant Protein-1 Increases Collateral and Peripheral Conductance After Femoral Artery Occlusion", Circ Res, June 1997, pgs 829-837, Vol. 80, No. 6.	
		WEIHRAUCH D. et al. "Repetitive Coronary Artery Occlusions Induce Release of Growth Factors into the Myocardial Interstitium", Am. J. Physiol., 1998, pgs H969-76.	
		WOLF C. et al., "Vascular Remodeling and Altered Protein Expression During Growth of Coronary Collateral Arteries", J Mol. Cell. Cardiol., 1998, pgs 2291-2305, Vol. 30, Academic Press.	
		ARRAS M. et al., "Monocyte Activation in Angiogenesis and Collateral Growth in the Rabbit Hindlimb", Journal of Clinical Investigation, Jan 1, 1998, pgs 40-50, Vol 101, No. 1.	
		ITO W. et al., "Collateral Artery Growth" Local Drug Delivery Meeting and Cardiovascular Course on Radiation & Molecular Strategies, Feb 26-28, 1998, Geneva, Switzerland.	
		DEINDL E. et al., "VEGF, An Important Angiogenic Factor is Not Involved in Arteriogenesis" Journal of Molecular Medicine, May 1998, pgs. B24, P-85.	
<i>W</i>		DEINDL E. et al., "Arteriogenesis Is Not Mediated By VEGF", Journal of Molecular and Cellular Cardiology, June 1998, pgs A127, #497, Vol 30, No. 6.	

Examiner Signature	<i>S</i>	Date Considered	6/4/08
--------------------	----------	-----------------	--------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) in this box

AUG 6 2001

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A (modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if known</b>	
Sheet	4	of	5	Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Assigned
				Attorney Docket Number	03764.P142


**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
<i>SC</i>		GOURDIE R. et al., "Endothelin-Induced Conversion of Embryonic Heart Muscle Cells Into Impulse-Conducting Purkinje Fibers", Proc Natl Acad Sci USA, June 9, 1998, pgs 6815-6818, Vol. 95, No. 12.			
		HOFER I. et al., "MCP-1 Increases the Number of Collaterals and Capillaries in the Rabbit Hindlimb", Journal of Molecular and Cellular Cardiology, June 1998, pgs A126, #495, Vol. 30, No. 6.			
		TEREB D. et al., "In Vivo Model for Coronary Artery Studies", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #157, Vol. 30, No. 6.			
		SCHEINOWITZ M. et al., "Fragmin Does Not Affect Left Ventricular Perfusion And Function Following Acute MI in Swine", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #158, Vol. 30, No. 6.			
		VOSSCHULTE R. et al., "Extracellular Proteolysis is Essential For Coronary Arteriogenesis", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #159, Vol. 30, No. 6.			
		TSUJIMURA S. et al., "Enhanced Expression of VEGF mRNA And Angiogenic Activity After Acute Myocardial Infarction (AMI) in Rats", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #160, Vol. 30, No. 6.			
		IWAKURA A. et al., "Coronary Stenosis and Mechanisms of Collateral Vessel Growth" Nippon Rinsho, Oct 1998, pgs 2504-2508, Vol. 56, No. 10.			
		INOUE M. et al., "Vascular Endothelial Growth Factor (VEGF) Expression in Human Coronary Atherosclerotic Lesions: Possible Pathophysiological Significance of VEGF in Progression of Atherosclerosis", Circulation, Nov 1998, pgs 2108-2116, Vol. 98, No. 20.			
		BUSCHMANN I. et al., "Attraction of Loaded Monocytes Via MCP-1: A Novel Strategy For Therapeutic Arteriogenesis", Oral Presentations: Max Planck Institute, Dept. for Experimental Cardiology, 1999.			
		<a href="http://www.naturalbypass.com">www.naturalbypass.com</a> , Vasomedical, Inc., Dec 3, 1999.			
		SORAN O. et al., "Enhanced External Counterpulsation in the Management of patients with Cardiovascular Disease", Clin Cardiol, 1999, pgs 173-8, Vol. 22.			
		VOELCKEL W. et al., "Effect of small dose dopamine on mesenteric blood flow and renal function in a pig model of cardiopulmonary resuscitation with vasopressin", Anesth Analg, 1999, pgs 1430-6, Vol. 89.			
		MACRIS M. et al., "Minimally Invasive Access of the Normal Pericardium: Initial Clinical Experience With a Novel Device", Clin Cardiol, Jan 1999, pgs I36-I39, Vol. 1 Suppl 1.			
		FLEISCH M. et al., "Direct Relation Between Quantitatively Determined Coronary Collateral Flow and Intracorony Basic Fibroblast Growth Factor Concentration", Oral Presentation: Session – Basic Aspects of Gene Therapy and Angiogenesis, Morial Convention Center, Room 222, March 9, 1999, Abstract 826-5.			
		GIBSON M. et al., "Magnitude and Location of New Angiographically Apparent Coronary Collaterals Following Intravenous VEGF Administration", Oral Presentation: Session – Intractable Angina: Trials of Vascular Growth Factors, Morial Convention Center, Room 345, March 10, 1999, Abstract 874-5.			
		ISNER J. et al., "Angiogenesis and Vasculogenesis as Therapeutic Strategies for Postnatal Neovascularization", The Journal of Clinical Investigation, May 1999, pgs 1231-1236, Vol. 103, No. 9.			
<i>✓</i>		BUSCHMANN I. et al., "Arteriogenesis Versus Angiogenesis: Two Mechanisms of Vessel Growth" News Physiol. Sci., June 1999, pgs. 121-125, Vol. 14.			

Examiner Signature	<i>Joe</i>	Date Considered	6/4/08
--------------------	------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



Guidant Disclosure Number: 1800, 20

PTO/SB/08A (08-00)

Please type a plus sign (+) in this box **0+6**


Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through January 1, 2012. GPO:2009-083-003.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form <del>1-7615-AUTO</del> PTO            (modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>            (use as many sheets as necessary)</p>				<i>Complete if known</i>	
				Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Assigned
				Attorney Docket Number	03764.P142
Sheet	5	of	5		

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	6/4/08
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Unique citation designation number.** <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**COPY OF PAPERS  
ORIGINALLY FILED.**

RECEIVED

AUG 14 2002

TECHNOLOGY CENTER R3700

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Exam. Initial*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)				
<i>See</i>		WIPO	WO99/49773	A2	Payne, Sam G. et al.	10/07/1999		
		WIPO	WO97/23256	A1	Kaplan, Arron V. et al.	07/03/1997		
		WIPO	WO96/39830	A1	March, Keith L. et al.	12/19/1996		
<i>✓</i>		EPO	0 383 429	A2	Wolinsky, Harvey et al.	08/22/1990		

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard S.3). <sup>4</sup>For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document.

\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


115 1 2 2002

**COPY OF PAPERS  
ORIGINALLY FILED**

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket No. 03764.P142

## U.S. PATENT DOCUMENTS

Exmnr Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
SN		us-3,978,055	B1	08/31/1976	Fauran et al.	
		us-5,713,860	B1	02/03/1998	Kaplan et al.	
		us-5,753,504	B1	05/19/1998	Kirkland et al.	
		us-5,792,106	B1	08/11/1998	Mische	
		us-5,852,175	B1	12/22/1998	Cummings et al.	
		us-5,877,295	B1	03/02/1999	Diamond et al.	
		us-5,959,087	B1	09/28/1999	Rathjen et al.	
		us-5,985,307	B1	11/16/1999	Hanson et al.	
		us-6,019,969	B1	02/01/2000	Cerami et al.	
		us-6,048,332	B1	04/11/2000	Duffy et al.	
		us-6,123,939	B1	09/26/2000	Shawver et al.	
V		us-6,169,077	B1	01/02/2001	Oehrlein	
		us-				
		us-				
		us-				

RECEIVED  
OCT 15 2003  
BIOLOGY CENTER R3700

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Exmnr Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>				


**Examiner  
Signature**

Date  
Considered

6/4/88

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Examiner  
Signature

Date  
Considered

6/4/08

*\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English Translation is attached.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.